RYTM
Income statement / Annual
Last year (2023), Rhythm Pharmaceuticals, Inc.'s total revenue was $77.43 M,
an increase of 227.56% from the previous year.
In 2023, Rhythm Pharmaceuticals, Inc.'s net income was -$184.68 M.
See Rhythm Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$77.43 M
|
$23.64 M
|
$3.15 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$9.30 M |
$2.13 M |
$599,000.00 |
$690,000.00 |
$834,000.00 |
$442,000.00 |
$223,000.00 |
$144,000.00 |
$0.00 |
$0.00 |
| Gross Profit |
$68.13 M |
$21.51 M |
$2.56 M |
-$690,000.00 |
-$834,000.00 |
-$442,000.00 |
-$223,000.00 |
-$144,000.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.88 |
0.91 |
0.81 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$134.95 M
|
$108.63 M
|
$104.13 M
|
$90.45 M
|
$109.45 M
|
$50.34 M
|
$22.89 M
|
$19.59 M
|
$7.15 M
|
$5.28 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$28.08 M
|
$9.52 M
|
$6.31 M
|
$3.43 M
|
$1.21 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$117.53 M
|
$92.03 M
|
$68.49 M
|
$46.13 M
|
$36.55 M
|
$28.08 M
|
$9.52 M
|
$6.31 M
|
$3.43 M
|
$1.21 M
|
| Other Expenses |
$0.00 |
-$790,000.00 |
$100.00 M |
$0.00 |
$0.00 |
$0.00 |
-$1.86 M |
$0.00 |
-$500,000.00 |
$0.00 |
| Operating Expenses |
$252.48 M |
$200.66 M |
$172.61 M |
$136.58 M |
$146.00 M |
$78.42 M |
$32.41 M |
$25.91 M |
$10.57 M |
$6.49 M |
| Cost And Expenses |
$261.79 M |
$202.80 M |
$173.21 M |
$136.58 M |
$146.00 M |
$78.42 M |
$32.41 M |
$25.91 M |
$10.57 M |
$6.49 M |
| Interest Income |
$13.95 M |
$4.03 M |
$447,000.00 |
$2.58 M |
$5.27 M |
$4.35 M |
$566,000.00 |
$33,000.00 |
$0.00 |
$0.00 |
| Interest Expense |
$13.89 M |
$5.20 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.76 M
|
$1.40 M
|
$1.16 M
|
$690,000.00
|
$834,000.00
|
$442,000.00
|
$223,000.00
|
$144,000.00
|
$500,000.00
|
$6.49 M
|
| EBITDA |
-$168.46 M
|
-$174.52 M
|
-$68.45 M
|
-$135.89 M
|
-$145.17 M
|
-$77.98 M
|
-$32.19 M
|
-$25.76 M
|
-$10.07 M
|
$0.00
|
| EBITDA Ratio |
-2.18 |
-7.44 |
-53.92 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-2.38
|
-7.58
|
-53.92
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$243,000.00
|
-$1.96 M
|
$100.45 M
|
$2.58 M
|
$5.27 M
|
$4.35 M
|
-$1.30 M
|
$33,000.00
|
-$500,000.00
|
$0.00
|
| Income Before Tax |
-$184.11 M |
-$181.12 M |
-$69.61 M |
-$134.00 M |
-$140.73 M |
-$74.06 M |
-$33.71 M |
-$25.87 M |
-$11.07 M |
-$6.49 M |
| Income Before Tax Ratio
|
-2.38
|
-7.66
|
-22.07
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$564,000.00 |
$1.96 M |
-$1.61 M |
-$3.27 M |
-$6.11 M |
$4.35 M |
$1.07 M |
$0.00 |
$0.00 |
$0.00 |
| Net Income |
-$184.68 M |
-$183.08 M |
-$68.01 M |
-$130.73 M |
-$134.62 M |
-$74.06 M |
-$33.71 M |
-$25.87 M |
-$11.07 M |
-$6.49 M |
| Net Income Ratio |
-2.39 |
-7.75 |
-21.56 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-3.2 |
-3.51 |
-1.37 |
-2.96 |
-3.7 |
-2.39 |
-2.54 |
-1.55 |
-0.66 |
-0.64 |
| EPS Diluted |
-3.2 |
-3.51 |
-1.37 |
-2.96 |
-3.7 |
-2.39 |
-2.54 |
-1.55 |
-0.66 |
-0.64 |
| Weighted Average Shares
Out |
$57.67 M
|
$52.12 M
|
$49.60 M
|
$44.13 M
|
$36.42 M
|
$31.00 M
|
$13.27 M
|
$16.73 M
|
$16.73 M
|
$10.20 M
|
| Weighted Average Shares
Out Diluted |
$57.67 M
|
$52.12 M
|
$49.60 M
|
$44.13 M
|
$36.42 M
|
$31.00 M
|
$13.27 M
|
$16.73 M
|
$16.73 M
|
$10.20 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
